Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

OSI Pharmaceuticals updates anticancer programs

Nov. 13, 1998

Favorable phase III trial results presented for Evacet at ESMO; company prepares NDA

Nov. 12, 1998

Small-molecule FGFR-1 tyrosine kinase inhibitor with nanomolar potency and good selectivity

Nov. 12, 1998

Protein tyrosine kinase inhibitors for cancer, polycystic kidney disease

Nov. 12, 1998

New anticancer drug candidate revealed by Sugen; product enters phase I testing in U.K.

Nov. 11, 1998

Promising interim results announced for SU-5416 phase I trial

Nov. 10, 1998

Two major clinical studies demonstrate chemo- and radioprotective activity of amifostine

Nov. 10, 1998

Ribozyme initiates phase I clinical trials of Angiozyme

Nov. 9, 1998

GBC-590 effective in murine model of treatment-resistant pancreatic cancer

Nov. 9, 1998

Progen commences phase I trials of PI-88 in the U.K.

Nov. 6, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...